Artificial Pancreas Device System (APDS) Market Prophesied to Grow at a Faster Pace by 2026 Analysis By Leading Players Johnson & Johnson, Medtronic, Medtrum, Beta Bionics, Bigfoot Biomedical

Eating habits of type 1 diabetes patients is highly curtailed, complemented by regular administration of insulin. Type 1 diabetes patients require multiple doses of insulin in a day and all-round the year. Advancements in research and technology has led to commercialization of easy-to-us insulin delivery systems such as insulin pens, pumps, inhaled insulin, and injectors. Use of syringes to deliver insulin has become obsolete with the introduction of advanced and easy-to-use insulin delivery systems mentioned above. Moreover, these systems offer the convenience to self-administer insulin at home. An artificial pancreas is a novel concept that promises to revolutionize the entire diabetes market. The system automatically detects glucose level in patient’s blood or plasma and accordingly administers the necessary dosage of insulin. Medtronic’s MiniMed 670G is one such wearable artificial pancreas. The system is automated to monitor glucose levels and deliver insulin through an insulin pump attached to the system. The artificial pancreas system comprises a transmitter, sensor, and insulin pump. This helps in continuous monitoring and diabetes management at ease.

Available Exclusive Sample Copy of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/79

Market Dynamics:

The artificial pancreas device system (APDS) market growth would be mainly driven by increasing adoption of the highly useful systems the large base of diabetes type 1 patients, further supplemented by ever increasing incidence of type 1 diabetes. According to the World Health Organization (WHO), number of diabetes patients worldwide increased from 108 million in 1980 to 422 million in 2014. According to Juvenile Diabetes Research Foundation (JDRF), there were around 1.5 million type 1 diabetics worldwide in 2015. JDRF funds research in diabetes 1 and the non-profit organization expected the first artificial pancreas to be commercialized in 2017. According to the Center for Disease Control and Prevention (CDC), type 1 diabetes accounts for around 5% of the total diagnosed diabetes cases in adults in the U.S. Developed regions are expected to dominate the artificial pancreas device system (APDS) market size, as these regions are early adopters of disruptive technologies. With the introduction of this technology, market for insulin pens and injectors is expected to be impacted negatively.

Market Taxonomy:

This report segments the global artificial pancreas device system (APDS) market on the basis of technology, distribution channel, end user and geography. On the basis of technology, the global artificial pancreas device system (APDS) market is categorized into Treat to Range/Control to Range (TTR/CTR), Treat to Target/ Control to Target (TTR/CTT) and Threshold Suspended Device Systems. On the basis of distribution channel the global artificial pancreas device system (APDS) market is segmented into e-commerce, Standalone Retail Shops and hospitals. End user of the APDS include type 1 and type 2 diabetic patients. For comprehensive understanding of market dynamics, the global artificial pancreas device system (APDS) market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Technological advancements to drive growth of the global artificial pancreas device system (APDS) market

In 2016, the U.S. FDA approved a hybrid closed-loop artificial pancreas device system (APDS) MiniMed 670G which is an automated system. The continuous glucose monitor in the system automatically sends signals to the insulin pump to deliver insulin when the glucose level in body goes beyond the acceptable limit. Thus, there is no need for the user to stimulate the release of insulin every time the glucose level is abnormal. This provide the user freedom to perform his/her daily activities. Such advancement in T1D management is expected to be highly preferred by the users and medical community, leading to higher advocacy to use this device especially among the patient group using insulin pumps. Moreover, in mid-2018, a study will test a bihormonal “bionic pancreas” system at the Massachusetts General Hospital (Boston) and Boston University. This would further fuel the artificial pancreas device system (APDS) market growth and attract more investments.

Key players operating in the global Artificial Pancreas Device System (APDS) market:

• Medtronic
• Medtrum
• Tandem Diabetes Care, Inc.
• Johnson & Johnson
• Beta Bionics
• Bigfoot Biomedical
• Insulet Corporation

Detailed Segmentation:

Global Artificial Pancreas Device System (APDS) Market, By Technology:

• Threshold Suspended Device Systems
• Treat to Range/Control to Range (TTR/CTR)
• Treat to Target/ Control to Target (TTR/CTT)

Global Artificial Pancreas Device System (APDS) Market, By Distribution Channel:

• E-commerce
• Standalone Retail Shops
• Hospitals

Global Artificial Pancreas Device System (APDS) Market, By End User:

• Type 1 Diabetic Patients
• Type 2 Diabetic Patients

Global Artificial Pancreas Device System (APDS) Market, By Geography:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Grab Your Report at an Impressive Discount @ https://www.coherentmarketinsights.com/insight/request-discount/79

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.